The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Pregabalin: a new anxiolytic
Abstract
Pregabalin (S-[+]-3-isobutylgaba) was designed as a lipophilic GABA (gamma-aminobutyric acid) analogue substituted at the 3'-position in order to facilitate diffusion across the blood-brain barrier. It was originally developed as an anticonvulsant agent, however it has been shown to be effective in the treatment of several disorders including hyperalgesia and behavioural disorders. Although its exact mode of action remains unclear, pregabalin interacts with the same binding site and has a similar pharmacological profile as its predecessor, gabapentin (1-[aminomethyl] cyclohexane acetic acid). Its main site of action appears to be on the alpha(2)delta subunit of voltage-dependent calcium channels, widely distributed throughout the peripheral and central nervous system. Pregabalin appears to produce an inhibitory modulation of neuronal excitability. In healthy volunteers, it is rapidly absorbed with peak blood concentrations within 1 h and it has a bioavailability of approximately 90%. In preclinical trials of anticonvulsant activity, pregabalin is three to ten times more potent than gabapentin. It is well-tolerated and associated with dose-dependent adverse effects (ataxia, dizziness, headache and somnolence) that are mild-to-moderate and usually transient. There are no known pharmacokinetic drug-drug interactions reported to date. Preliminary animal and human studies showed beneficial effects in both ethological and conflict models of anxiety, as well as having some sleep-modulating properties. In Phase II and III trials, pregabalin shows promising anxiolytic action when compared to placebo in generalised anxiety disorder, social phobia and panic disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Backonja, M. (1998) · JAMA · doi:10.1001/jama.280.21.1831 · Cited by 1,533
Rowbotham, M. (1998) · JAMA · doi:10.1001/jama.280.21.1837 · Cited by 1,433
The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the α2δ Subunit of a Calcium Channel
Gee, N. S., Brown, J. P., Dissanayake, V. U. K., Offord, J., Thurlow, R., & Woodruff, G. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5768 · Cited by 1,181
Schneier (1992) · doi:10.1001/archpsyc.1992.01820040034004 · Cited by 1,142
Past-Year Use of Outpatient Services for Psychiatric Problems in the National Comorbidity Survey
Kessler, R. C., Zhao, S., Katz, S. J., Kouzis, A. C., Frank, R. G., Edlund, M., & Leaf, P. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.115 · Cited by 610
Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex
Fink, K., Dooley, D. J., Meder, W. P., Suman-Chauhan, N., Duffy, S., Clusmann, H., & Göthert, M. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(01)00172-1 · Cited by 496
Kessler, R. C., DuPont, R. L., Berglund, P., & Wittchen, H.-U. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1915 · Cited by 486
Treatment of Social Phobia With Gabapentin: A Placebo-Controlled Study
Pande, A. C., Davidson, J. R. T., Jefferson, J. W., Janney, C. A., Katzelnick, D. J., Weisler, R. H., Greist, J. H., & Sutherland, S. M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199908000-00010 · Cited by 395
Field, M. J., Oles, R. J., Lewis, A. S., McCleary, S., Hughes, J., & Singh, L. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701320 · Cited by 326
Stewart, B. H., Kugler, A. R., Thompson, P. R., & Bockbrader, H. N. (1993) · Pharmaceutical Research · doi:10.1023/a:1018951214146 · Cited by 309
3-Substituted GABA analogs with central nervous system activity: A review
Bryans, J. S., & Wustrow, D. J. (1999) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199903)19:2<149::aid-med3>3.0.co;2-b · Cited by 297
Field, M. J., McCleary, S., Hughes, J., & Singh, L. (1999) · Pain · doi:10.1016/s0304-3959(98)00239-5 · Cited by 295
Gabapentin Adjunctive Therapy in Neuropathic Pain States
Rosner, H., Rubin, L., & Kestenbaum, A. (1996) · The Clinical Journal of Pain · doi:10.1097/00002508-199603000-00010 · Cited by 293
Evaluation of Gabapentin and S-(+)-3-Isobutylgaba in a Rat Model of Postoperative Pain
Field, M. J., Holloman, E. F., McCleary, S., Hughes, J., & Singh, L. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36908-3 · Cited by 248
Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin
Dooley, D. J., Mieske, C. A., & Borosky, S. A. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00769-2 · Cited by 226
Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies
Suman-Chauhan, N., Webdale, L., Hill, D. R., & Woodruff, G. N. (1993) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(93)90155-3 · Cited by 225
Dooley, D. J., Donovan, C. M., & Pugsley, T. A. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39009-3 · Cited by 217
The Effect of Gabapentin on Neuropathic Pain
Rosenberg, J. M., Harrell, C., Ristic, H., Werner, R. A., & de Rosayro, A. M. (1997) · The Clinical Journal of Pain · doi:10.1097/00002508-199709000-00011 · Cited by 214
The New Generation of GABA Enhancers: Potential in the Treatment of Epilepsy
Czuczwar, S. J., & Patsalos, P. N. (2001) · CNS Drugs · doi:10.2165/00023210-200115050-00001 · Cited by 209
A double‐blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus
Averbuch‐Heller, L., Tusa, R. J., Fuhry, L., Rottach, K. G., Ganser, G. L., Heide, W., Büttner, U., & Leigh, R. J. (1997) · Annals of Neurology · doi:10.1002/ana.410410620 · Cited by 205
Reflex sympathetic dystrophy treated with gabapentin
Mellick, G. A., & Mellick, L. B. (1997) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(97)90020-4 · Cited by 204
Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database
Khan, A., Leventhal, R. M., Khan, S., & Brown, W. A. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00354-8 · Cited by 190
Maneuf, Y. P., Hughes, J., & McKnight, A. T. (2001) · Pain · doi:10.1016/s0304-3959(01)00316-5 · Cited by 184
Fink, K., Meder, W., Dooley, D. J., & Göthert, M. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703380 · Cited by 169
Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies
Hill, D. R., Suman‐Chauhan, N., & Woodruff, G. N. (1993) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(93)90156-4 · Cited by 155
Ng, G., Bertrand, S. S., Sullivan, R. J., Éthier, N., Wang, J. P., Yergey, J. A., Belley, M. L., Trimble, L. A., Bateman, K. P., Alder, L., et al. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.1.144 · Cited by 153
Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis
Miller, R. G., Moore, D., Young, L., Armon, C., Barohn, R. J., Bromberg, M. B., Bryan, W. W., Gelinas, D. F., Mendoza, M. C., Neville, H. E., et al. (1996) · Neurology · doi:10.1212/wnl.47.6.1383 · Cited by 152
Taylor, C. P., Vartanian, M. G., Yuen, P., et al. (1993) · Epilepsy Research · doi:10.1016/0920-1211(93)90070-n · Cited by 150
Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity
Field, M. J., Oles, R. J., & Singh, L. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703794 · Cited by 129
Vincristine-induced allodynia in the rat
Nozaki‐Taguchi, N., Chaplan, S. R., Higuera, E. S., Ajakwe, R., & Yaksh, T. L. (2001) · Pain · doi:10.1016/s0304-3959(01)00294-9 · Cited by 126
Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis
Mueller, M. E., Gruenthal, M., Olson, W. L., & Olson, W. H. (1997) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(97)90168-4 · Cited by 121
Treatment of Restless Legs Syndrome with Gabapentin
Adler, C. H. (1997) · Clinical Neuropharmacology · doi:10.1097/00002826-199704000-00006 · Cited by 117
Open label gabapentin treatment for pain in multiple sclerosis
Houtchens, M. K., Richert, J. R., Sami, A., & ROSE, J. W. (1997) · Multiple Sclerosis Journal · doi:10.1177/135245859700300407 · Cited by 116
An open-lebel trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients
Solaro, C. M., Lunardi, G. L., Capello, E., Inglese, M., Uccelli, M. M., Uccelli, A., & Mancardi, G. (1998) · Neurology · doi:10.1212/wnl.51.2.609 · Cited by 111
Bačkonja, M.-M. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb00934.x · Cited by 79
Chen, S.-R., Xu, Z., & Pan, H. (2001) · Anesthesiology · doi:10.1097/00000542-200112000-00029 · Cited by 74
Psychiatric and Somatic Markers of Anxiety
Gelenberg, A. J. (2000) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v02n0204 · Cited by 72
Andrews, N., Loomis, S., Blake, R., Ferrigan, L., Singh, L., & McKnight, A. T. (2001) · Psychopharmacology · doi:10.1007/s002130100839 · Cited by 68
Antiepileptic Drugs in Migraine Prevention
Mathew, N. T. (2001) · Headache The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2001.01154-4.x · Cited by 59
Metabolic disposition of pregabalin in healthy volunteers
Corrigan, B., Pool, W. F., Posvar, E. L., Strand, J. C., Alvey, C. W., Radulovic, L. L., & Bockbrader, H. N. (2001) · Clinical Pharmacology & Therapeutics · Cited by 58
Effect of gabapentin (neurotonin®) on mood and well-being in patients with epilepsy
Dimond, K. R., Pande, A. C., LaMoreaux, L., & Pierce, M. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(96)00005-x · Cited by 55
New Measures of Outcome Needed for the Surgical Treatment of Epilepsy
Taylor, D. C., Neville, B. G. R., & Cross, J. H. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01230.x · Cited by 50
Houghton, A. K., Lu, Y., & Westlund, K. N. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37417-8 · Cited by 47
Pregabalin pharmacokinetics and safety in healthy volunteers Results from two phase 1 studies
Bockbrader, H. N., Hunt, T. L., Strand, J. J., Posvar, E. L., & Sedman, A. J. (2000) · Cited by 36
Ballenger, J. C., Davidson, J. R. T., Lecrubier, Y., & Nutt, D. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0201 · Cited by 31
A placebo-controlled study of pregabalin and venlafaxine treatment of GAD
Kasper, S. F., Blagden, M., Seghers, S., Veerman, A., Volz, H., Geniaux, A., Strub, N., Marchand, A., Maisonobe, P., & Mikkelsen, H. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)80535-1 · Cited by 15
Feltner, D. E., Pollack, M. H., Davidson, J. R. T., Stein, M. B., Futterer, R., Jefferson, J. W., Lydiard, R. B., DuBoff, E., Robinson, P., Phelps, M. C., et al. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80439-3 · Cited by 12
Cited by
The importance of Green Chemistry in Process Research and Development
Dunn, P. J. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15041c · Cited by 604
Field, M. J., Cox, P. J., Stott, E., Melrose, H., Offord, J., Su, T.-Z., Bramwell, S., Corradini, L., England, S., Winks, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409066103 · Cited by 591
Pregabalin Pharmacology and Its Relevance to Clinical Practice
Ben‐Menachem, E. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.455003.x · Cited by 542
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
Anxiety in patients with epilepsy: Systematic review and suggestions for clinical management
Beyenburg, S., Mitchell, A. J., Schmidt, D., Elger, C. E., & Reuber, M. (2005) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2005.05.014 · Cited by 371
Metadata
- Authors
- Lauria-Horner, B. A., & Pohl, R. B.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2003-04
- Volume
- 12
- Issue
- 4
- Pages
- 663-672
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2152775636
- Cited by
- 327
- References
- 48
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.